Neobiosis Appoints Pascal Goldschmidt, M.D. as Chief Medical Officer

Press Release – updated: May 30, 2021 08:00 EDT

ALACHUA, Fla., May 30, 2021 (Newswire.com) –
Neobiosis, a clinical-stage contract development and manufacturing organization, managed by scientists and physicians and focused on the science of regenerative medicine, today announced the appointment of Pascal Goldschmidt, M.D. as Chief Medical Officer.

As CMO Dr. Goldschmidt will oversee the clinical translation of Neobiosis’ regenerative products through Investigational New Drug (IND) applications with the FDA and into clinical trials. Dr. Goldschmidt is an accomplished cardiologist, professor, academic healthcare leader, and medical researcher. He has served as a Tenured Professor at three prestigious institutions, Duke University School of Medicine, Ohio State University (OSU) and University of Miami. He was Center Director at Johns Hopkins University School of Medicine, Chief of Cardiology at OSU, then at Duke, and Chairman of Medicine at Duke. In 2006, he became Dean of the Miller School of Medicine and Founder/CEO of UHealth, the University of Miami Health System.

“We are delighted to welcome Dr. Goldschmidt to the Neobiosis leadership. He brings with him a strong history in industry and operational leadership at a time when our lead product candidates are advancing to the clinic,” said Ian White, Ph.D., Founder, President and Chief Scientific Officer of Neobiosis. “Pascal has extensive experience in biological drug development, which is critical for our clinical development and registration goals. His career-long focus on patient quality of care is an excellent fit with our vision and philosophy, which is committed to making meaningful differences in patients’ lives.”

“This appointment is reflective of Neobiosis’ strength in the field of Regenerative Medicine and represents Neobiosis’ commitment to advancing our pipeline of biological therapeutic candidates though FDA-compliant avenues towards approval,” added Owen Carhart, Co-founder and Chief Executive Officer of Neobiosis.

Dr. Goldschmidt and his team expanded UHealth to include the medical practice, three hospitals, and major outpatient clinic facilities along both coasts of South Florida. Clinical revenues increased three-fold over a ten-year period, which represented one of the fastest compound annual growth rate for academic medical centers in the USA.

“I am delighted to join the leadership and team of Neobiosis, a company focused on producing and delivering products that transform lives and have been refined by nature itself over millions of years,” stated Dr. Goldschmidt. “Neobiosis is unique in the field of regeneration because it believes in, and produces, high quality science, and its approach to regenerative medicine is truly holistic, thus promoting tissue repair, regeneration and wellbeing. This is a very exciting opportunity.”

During his tenure at the University of Miami, the Leonard M. Miller School of Medicine rose up 13 positions (from 51 to 38 out of 177 United States Medical Schools) in the national rankings of research medical schools based on grants received from the National Institutes of Health, thus establishing this School as the highest-ranked medical school in Florida. To achieve this, Dr. Goldschmidt established new Institutes and Centers focused on team science and big data such as human genetics/genomics and stem cell science, that brought in groundbreaking new knowledge, jobs, millions of dollars in research funding, and poised the Miller School and UHealth for continued excellence. 

Dr. Goldschmidt has a long list of honors and awards, beginning in 1980 with his graduation as a medical doctor and Valedictorian of Class of 225 from the Université Libre de Bruxelles. The list of his patents, publications, articles numbers more than 300. His 250 invited lectureships and speaking engagements are testimony to his professional expertise.

About Neobiosis
Neobiosis, LLC is a clinical-stage contract development and manufacturing organization (CDMO) managed by scientists and physicians focused on the science of regenerative medicine. They produce regenerative medicines from perinatal tissues, cells and secretome for research and clinical trials. Regenerative medicine taps into the body’s innate ability to heal itself relieving pain without opioids, being more cost effective and safer than many surgical alternatives. Neobiosis is an FDA-registered CDMO operating under current Good Manufacturing Practice (cGMP) standards with ISO7 cleanroom laboratories located in Alachua and Gainesville, FL. Visit https://neobiosis.com

Source: Neobiosis, LLC